By Professor Michael Leonard Friedlander

Journal articles

Bonevski B; Sanson-Fisher R; Girgis A; Burton L; Cook P; Boyes AW; Ackland S; Baker RW; Berry M; Biggs J, 2000, 'Evaluation of an instrument to assess the needs of patients with cancer', Cancer, 88, pp. 217 - 225

Friedlander ML, 1999, 'Multivariate prognostic models in ovarian cancer', CME Journal of Gynecologic Oncology, 4, pp. 256 - 258

Friedlander ML, 1999, 'Surgical stage, ascites, peritoneal cytology, tumour spillage, dense adherence', CME Journal of Gynecologic Oncology, 4, pp. 38 - 40

Meiser B; Butow P; Barratt A; Friedlander M; Gattas M; Kirk J; Suthers G; Walpole I; Tucker K, 1999, 'Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer', Gynecologic Oncology, 75, pp. 122 - 129, http://dx.doi.org/10.1006/gyno.1999.5544

Links MJ; Watson SR; Lethlean K; Aherne W; Kirsten F; Clarke SP; Law MG; Friedlander ML; Galettis P; Mckeage M, 1999, 'Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin', Cancer Investigation, 17, pp. 479 - 485

Friedlander M, 1998, 'A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer', Annals of Oncology, 9, pp. 1343 - 1345, http://dx.doi.org/10.1023/A:1008469212268

Friedlander ML, 1998, 'Prognostic factors and tumour markers in ovarian teratomas', CME Journal of Gynecologic Oncology, 3, pp. 177 - 180

Friedlander ML, 1998, 'Prognostic factors in ovarian cancer', Seminars in Oncology, 25, pp. 305 - 314

Kefford R; Tucker K; Friedlander M; Kirk J, 1998, 'Cancer in the family. Part 2.', Australian family physician, 27, pp. 40 - 44

Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J, 1998, 'Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer', Journal of Clinical Oncology, 16, pp. 1948 - 1953, http://dx.doi.org/10.1200/JCO.1998.16.5.1948

Hacker NF; Bancher-Todesca D; Williams KL; Neunteufel W; Friedlander ML, 1998, 'Influence of post operative treatment on survival in patients with uterine papillary serous carcinoma', Gynecologic Oncology, pp. 344 - 347

Links MJ; Ribeiro JC; Jackson P; Friedlander ML; Russell PJ, 1998, 'Regulation and deregulation of G2 checkpoint proteins with cisplatin', Anticancer Research, 18, pp. 4057 - 4066

Beller E; Tattersall M; Lumley T; Levi J; Dalley D; Olver I; Page J; Abdi E; Wynne C; Friedlander M; Boadle D; Wheeler H; Margrie S; Simes RJ, 1997, 'Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial', Annals of Oncology, 8, pp. 277 - 283, http://dx.doi.org/10.1023/A:1008291825695

Friedlander M, 1997, 'A menopausal woman with a history of breast cancer: Should she receive HRT?', Modern Medicine of Australia, 40, pp. 164 - 165

Michael M; Bishop JF; Levi JA; Bell DR; Zalcberg JR; Friedlander ML; Olver LN; Smith JG; Toner GC, 1997, 'Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy', Medical Journal of Australia, 166, pp. 520 - 523, http://dx.doi.org/10.5694/j.1326-5377.1997.tb123243.x

Kefford R; Tucker K; Friedlander M; Kirk J, 1997, 'Cancer in the family. Guidelines for general practice.', Australian family physician, 26, pp. 545 - 549

Friedlander M; De Gramont A; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Rippche V; Kayitalire L, 1997, 'Activity of Gemcitablne in stage 3 or 4 ovarian cancer: Patients previously treated with cisplatin (CP)-containing regimens', European Journal of Cancer, 33, pp. S120 - S121, http://dx.doi.org/10.1016/s0959-8049(97)85054-x

Friedlander ML; Kerr JL; Hurst T; Shih A; Purdie DM; Bergman L; Chenevix-Trench G; Sanderson B; Zournazi A; Coombs T; Leary JA; Crawford E; Shelling AN; Cooke I; Ganesan TS; Searle J; Choi J; Barrett JW; Khoo SK; Ward B, 1997, 'Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinicopathological correlations', Genes Chromosomes and Cancer, pp. 75 - 83

Friedlander ML; Tucker K, 1997, 'Hereditary ovarian cancer: genetic basic and management issues', Cancer Forum, 21, pp. 10 - 13

Kerr J; Leary JA; Hurst T; Shih YC; Antalis TM; Friedlander M; Crawford E; Khoo SK; Ward B; Chenevix-Trench G, 1996, 'Allelic loss on chromosome 7q in ovarian adenocarcinomas: Two critical regions and a rearrangement of the PLANH1 locus', Oncogene, 13, pp. 1815 - 1818

Zalcberg JR; Friedlander ML; Collopy BT; Barton M; Gray B, 1996, 'Treatment principles in advanced colorectal cancer (vol 66, pg 202, 1996)', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 66, pp. 503 - 503, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996UX20100021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kavallaris M; Leary JA; Barrett JA; Friedlander ML, 1996, 'MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors', Cancer Letters, 102, pp. 7 - 16, http://dx.doi.org/10.1016/0304-3835(96)04143-2

Zalcberg JR; Friedlander ML; Collopy BT; Barton M; Gray B, 1996, 'Erratum: Treatment principles in advanced colorectal cancer (Australian and New Zealand Journal of Surgery (1996) 66 (202-205))', Australian and New Zealand Journal of Surgery, 66, pp. 503

Millward MJ; Bishop JF; Friedlander M; Levi JA; Goldstein D; Olver IN; Smith JG; Toner GC; Rischin D; Bell DR, 1996, 'Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer', Journal of Clinical Oncology, 14, pp. 142 - 148, http://dx.doi.org/10.1200/JCO.1996.14.1.142

Zalcberg JR; Friedlander ML; Collopy BT; Barton M; Gray B, 1996, 'Treatment principles in advanced colorectal cancer', Australian and New Zealand Journal of Surgery, 66, pp. 202 - 205, http://dx.doi.org/10.1111/j.1445-2197.1996.tb01164.x

Phillips KA; Fitzharris B; Friedlander M; McCrystal M; Olver I; Joughin J; Bishop J; Evans B; Smith J, 1995, 'Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer', Australian and New Zealand Journal of Medicine, 25, pp. 337 - 343, http://dx.doi.org/10.1111/j.1445-5994.1995.tb01899.x

Links M; Friedlander M, 1995, 'High-dose chemotherapy in gynaecological cancers: Does more mean better?', Current Opinion in Obstetrics and Gynecology, 7, pp. 49 - 52, http://dx.doi.org/10.1097/00001703-199507010-00010

De Souza PL; Friedlander ML, 1995, 'Humoral hypercalcemia associated with adenocarcinoma of the rectum: A case report and review of the literature', American Journal of Clinical Oncology: Cancer Clinical Trials, 18, pp. 126 - 129, http://dx.doi.org/10.1097/00000421-199504000-00006

Leary JA; Kerr J; Chenevix‐Trench G; Doris CP; Hurst T; Houghton CRS; Friedlanders ML, 1995, 'Increased expression of the nme1 gene is associated with metastasis in epithelial ovarian cancer', International Journal of Cancer, 64, pp. 189 - 195, http://dx.doi.org/10.1002/ijc.2910640308

Shannon JA; Donnellan MJ; Friedlander ML; Harnett PR, 1995, 'Persisting elevation of alphafetoprotein after chemotherapy for germ cell tumour-not always due to viable malignancy?', European Journal of Cancer, 31, pp. 1722, http://dx.doi.org/10.1016/0959-8049(95)00303-Z

Zalcberg JR; Bishop JF; Millward MJ; Zimet A; Laird J; Barter C; Seward D; McKeage MJ; Friedlander ML; Toner G; Berille J; Blanc C, 1995, '1084 Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)', European Journal of Cancer, 31, pp. S226 - S226, http://dx.doi.org/10.1016/0959-8049(95)96330-g

Links M; Friedlander M, 1995, 'High-dose chemotherapy in gynaecological cancers', Current Opinion in Obstetrics and Gynecology, 7, pp. 49 - 52, http://dx.doi.org/10.1097/00001703-199502000-00010

Van Der Velden J; Gitch G; Wain GV; Friedlander ML; Hacker NF, 1995, 'Tamoxifen in patients with advanced epithelial ovarian cancer', International Journal of Gynecological Cancer, pp. 301 - 305

Gitch G; Friedlander ML; Wain GV; Hacker NF, 1995, 'Uterine papillary serous carcinaoma: a clinical study', Cancer, pp. 2239 - 2243

FRIEDLANDER M; LEWIS C; GOLDSTEIN D, 1994, 'UNTITLED', MEDICAL JOURNAL OF AUSTRALIA, 161, pp. 638 - 638, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994PT68600027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

SEGELOV E; FRIEDLANDER M, 1994, 'PROGNOSTIC FACTORS FOR WOMEN WITH OVARIAN GERM-CELL TUMORS - REPLY', JOURNAL OF CLINICAL ONCOLOGY, 12, pp. 1738 - 1738, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994PA25700031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chenevix-Trench G; Kerr J; Friedlander M; Hurst T; Sanderson B; Coglan M; Ward B; Leary J; Khoo SK, 1994, 'Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors', American Journal of Human Genetics, 55, pp. 143 - 149

Segelov E; Stuart-Harris R; Bell D; Tattersall M; Hutton-Potts J; Friedlander M, 1994, 'A phase II study of carboplatin and cisplatin in advanced ovarian cancer', European Journal of Gynaecological Oncology, 15, pp. 277 - 282

Segelov E; Campbell J; Ng M; Tattersall M; Rome R; Free K; Hacker N; Friedlander ML, 1994, 'Cisplatin-based chemotherapy for ovarian germ cell malignancies: The Australian experience', Journal of Clinical Oncology, 12, pp. 378 - 384, http://dx.doi.org/10.1200/JCO.1994.12.2.378

Quinn M; Murray J; Friedlander M; Steigrad S; Khoo S; Marsden D; Hammond I; Jobling T, 1994, 'EMACO in High Risk Gestational Trophoblast Disease ‐ The Australian Experience', Australian and New Zealand Journal of Obstetrics and Gynaecology, 34, pp. 90 - 92, http://dx.doi.org/10.1111/j.1479-828X.1994.tb01047.x

De Souza P; Friedlander M; Wilde C; Kirsten F; Ryan M, 1994, 'Hypersensitivity reactions to etoposide: A report of three cases and review of the literature', American Journal of Clinical Oncology: Cancer Clinical Trials, 17, pp. 387 - 389, http://dx.doi.org/10.1097/00000421-199410000-00005

Mayordomo JI; Paz-Ares L; Diaz-Puente MT; Lianes P; Garcia-Prats MD; Cortes-Funes H; Segelov E; Friedlander M, 1994, 'Prognostic factors for women with ovarian germ cell tumors [2]', Journal of Clinical Oncology, 12, pp. 1737 - 1738, http://dx.doi.org/10.1200/JCO.1994.12.8.1737

Mackintosh JF; Friedlander M; Lewis C; Goldstein D; Herrmann RP; Kearsley JH, 1994, 'Wanted: Guidelines for 'palliative' anti-cancer drug use [3]', Medical Journal of Australia, 161, pp. 638 - 639, http://dx.doi.org/10.5694/j.1326-5377.1994.tb127659.x

Lewis CR; Segelov E; Goldstein D; Friedlander ML, 1993, 'Chemotherapy made easier.', Australian and New Zealand journal of medicine, 23, pp. 387 - 392, http://dx.doi.org/10.1111/j.1445-5994.1993.tb01440.x

Leary JA; Doris CP; Boltz EM; Houghton CRS; Kefford RF; Friedlander ML, 1993, 'Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer 11p, 17p and 17q in ovarian cancer', International Journal of Gynecological Cancer, 3, pp. 293 - 298, http://dx.doi.org/10.1046/j.1525-1438.1993.03050293.x

Leary JA; Edwards BG; Houghton CRS; Kefford RF; Friedlander ML, 1992, 'Amplification of HER-2/neu oncogene in human ovarian cancer', International Journal of Gynecological Cancer, 2, pp. 291 - 294, http://dx.doi.org/10.1046/j.1525-1438.1992.02060291.x

Levi JA; Wheeler HR; Friedlander M; Tattersall MHN; Kefford R; Dalley D, 1992, 'Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix', Gynecologic Oncology, 45, pp. 329 - 333, http://dx.doi.org/10.1016/0090-8258(92)90314-9

Chenevix-Trench G; Leary J; Kerr J; Michel J; Kefford R; Hurst T; Parsons PO; Friedlander M; Khoo SK, 1992, 'Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus', Oncogene, 7, pp. 1059 - 1065

De Souza PL; Friedlander ML, 1992, 'Prognostic factors in ovarian cancer', Hematology/Oncology Clinics of North America, 6, pp. 761 - 781, http://dx.doi.org/10.1016/s0889-8588(18)30309-5

Friedlander M; De Souza P; Segelov E, 1992, 'Risk factors, epidemiology, screening, and prognostic factors in female genital cancer', Current Opinion in Oncology, 4, pp. 913 - 922, http://dx.doi.org/10.1097/00001622-199210000-00016

Back to profile page